预测抗体介导排斥反应肾移植受者移植肾存活的动态预后评分
该研究基于278例接受标准治疗的活跃ABMR患者,构建了整合诊断时与治疗后指标的动态预后评分,模型区分度良好(C-statistic=0.84),将患者分为高、中、低风险三组,6年移植肾存活率分别为6.0%、44.9%和84.4%,并在202例独立队列中验证(C-statistic=0.79)。
要点
- 动态ABMR预后评分可预测移植肾存活,区分高、中、低风险。
- 评分整合诊断时GFR、IF/TA及治疗后GFR变化、PTC Banff评分和DSA MFI。
- 高风险组6年移植肾存活率仅6.0%,低风险组达84.4%。
核心结论
- 动态ABMR预后评分能有效预测移植肾存活,并可用于指导治疗决策和临床试验设计。
研究设计与样本
- 研究纳入2008至2014年间278例诊断为活跃ABMR并接受标准治疗(血浆置换、静脉Ig和利妥昔单抗)的肾移植受者,前瞻性评估诊断时和治疗后的临床、组织学及DSA数据,并在202例独立队列中验证。
主要发现
- 预测模型包含诊断时GFR(P<0.001)和间质纤维化/肾小管萎缩(P=0.003),以及治疗后GFR变化(P<0.001)、管周毛细血管炎Banff评分(P=0.002)和DSA平均荧光强度(P<0.001)。
- 模型校准和区分度良好(C-statistic=0.84),验证队列C-statistic=0.79。
- 预后评分将患者分为高风险组(n=40,6年移植肾存活率6.0%)、中风险组(n=36,44.9%)和低风险组(n=202,84.4%)。
- 该评分比将所有患者视为相同风险提供更大的净临床获益。
关键数值与推荐
- 动态ABMR预后评分基于诊断时GFR、IF/TA及治疗后GFR变化、PTC Banff评分和DSA MFI计算。
- 高风险组6年移植肾存活率为6.0%,中风险组44.9%,低风险组84.4%。
临床怎么用
- 该评分可用于临床实践中对ABMR患者进行风险分层,辅助治疗决策,并可用于临床试验设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
No tool is available for the early assessment of response to antibody-mediated rejection (ABMR) therapies in kidney allograft recipients. This study was designed to define a dynamic composite prognostic ABMR score to predict kidney allograft survival, integrating the disease characteristics at diagnosis and the response to treatment. Among 1978 kidney recipients who underwent transplant between 2008 and 2014, we included 278 patients diagnosed with active ABMR and receiving standard treatment, including plasma exchange, intravenous Ig, and rituximab. Patients were prospectively assessed at diagnosis and after treatment for clinical data, histologic characteristics (allograft biopsy specimen), and donor-specific anti-HLA antibodies (DSA). The dynamic ABMR prediction model included GFR (P<0.001) and presence of interstitial fibrosis/tubular atrophy (P=0.003) at diagnosis and changes in GFR (P<0.001), peritubular capillaritis Banff score (P=0.002), and DSA mean fluorescence intensity (P<0.001) after treatment. Overall, this model showed good calibration and discrimination (C-statistic=0.84). The ABMR prognostic score derived from the prediction model identified three risk strata with 6-year kidney allograft survival rates of 6.0% (high-risk group, n=40), 44.9% (intermediate-risk group, n=36), and 84.4% (low-risk group, n=202), and it provided greater net clinical benefit to patients than did considering them all to have the same level of risk of allograft loss. The performance of the ABMR prognostic score was validated in an independent cohort of 202 kidney recipients with ABMR (C-statistic=0.79). The ABMR prognostic score could be used to inform therapeutic decisions in clinical practice and for the design of clinical trials.
引用
- Viglietti D, Loupy A, Aubert O, et al. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. J Am Soc Nephrol. 2017. PMID: 29255058. doi:10.1681/ASN.2017070749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。